-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – ibezapolstat
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry ibezapolstat Drug Details Ibezapolstat (ACX-362E) is under development for the treatment of Clostridium difficile...
-
Product Insights
Vancomycin-Resistant Enterococcus Faecium Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The Vancomycin-Resistant Enterococcus Faecium Infections pipeline drugs market research report provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Enterococcus Faecium Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report reviews key players involved in therapeutic development for...
-
Product Insights
Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The risk factors of Methicillin-Resistant Staphylococcus Aureus (MRSA) are hemodialysis, weakened immune system, admission to hospitals, and wounds. Symptoms include skin rashes, fatigue, chest pain, fever, and swelling. MRSA can be managed using antibiotics and by maintaining hygienic conditions The Methicillin-Resistant Staphylococcus Aureus pipeline market research report provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus Aureus, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The...
-
Product Insights
Clostridioides Difficile Infections (Clostridium Difficile Associated Disease) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Clostridioides difficile Infections – Drugs In Development, 2022, provides an overview of the Clostridioides difficile Infections (Infectious Disease) pipeline landscape. Clostridium difficile infections are caused by Clostridium difficile, often called C. difficile or C. diff, a bacterium that can cause symptoms ranging from diarrhea to life-threatening inflammation of the colon. Symptoms of C. diff infection includes watery diarrhea, with abdominal pain or tenderness, loss of appetite, fever, blood or pus...
-
Product Insights
Clostridium Difficile Infections (Clostridium Difficile Associated Disease) Disease – Global Clinical Trials Review, H1 2019
GlobalData's clinical trial report, “Clostridium difficile Infections (Clostridium difficile Associated Disease) Global Clinical Trials Review, H1, 2019" provides an overview of Clostridium difficile Infections (Clostridium difficile Associated Disease) clinical trials scenario. This report provides top line data relating to the clinical trials on Clostridium difficile Infections (Clostridium difficile Associated Disease). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7...